Johnson & Johnson (NYSE:JNJ) unit DePuy Synthes announced that it received FDA 510(k) clearance for the Velys system.
Velys is a robotic-assisted system designed for use with the Attune total knee system and its cleared indications for use and it will become part of the broader Velys digital surgery platform of connected technologies, according to a news release.
DePuy Synthes touts the Velys robotic-assisted platform as a first-of-its kind, table-mounted solution with an efficient design capable of integrating into any operating room. The company said it adapts to a surgeon’s workflow, offers control they are used to and heps execute accurate bony cuts.
Additionally, the Velys system offers gap balance data for visualization and joint stability predictions, along with accurate, consistent plan execution supporting the Attune total knee system.
Johnson & Johnson and DePuy Synthes acquired the Velys system as from its developer Orthotaxy in 2018.
“Globally, previous generation robotics have only penetrated key orthopaedic segments between 5-10% of the market,” DePuy Synthes company group chairman Aldo Denti said in a news release. “A significant opportunity for combined robotic and digital surgery technology exists. Coupled with the Attune total knee, the Velys robotic-assisted solution is highly differentiated and can help improve clinical outcomes and increase patient satisfaction, providing a more attractive clinical solution to current options on the market.
“With the addition of the Velys robotic-assisted solution to our Velys digital surgery platform, we are continuing our vision to be the most personalized and connected orthopaedics company.”
